Last updated date
ABOUT THIS STUDY
Patients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic Lymphoma Kinase (ALK) translocation, ROS1 mutation if available or MET exon 14 skipping mutation if available) will receive a tri-therapy associating avelumab, axitinib and palbociclib.
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage III
Females and Males
18 + years
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIISurvival Prolongation by Rationale Innovative Genomics
- La Jolla, California
- Sioux Falls, South Dakota
- Ramat Gan,